Showing 1891-1900 of 2192 results for "".
- Wearable Chest Sleep Apnea Test Receives FDA Clearancehttps://practicalneurology.com/news/wearable-chest-sleep-apnea-test-receives-fda-clearance/2470557/The Food and Drug Administration (FDA) has granted 510(k) clearance to SANSA (Huxley Medical, Atlanta, GA), a sleep apnea patch that is worn on the chest. SANSA is an at-home, single-point-of-contact diagnostic device that does not require additional attachments such as belts, wires, or hoses. Th
- Intranasal Foralumab Receives Fast Track Designation as Potential Tx for Non-Active SPMShttps://practicalneurology.com/news/intranasal-foralumab-receives-fast-track-designation-as-potential-tx-for-non-active-spms/2470554/An intranasal formulation for foralumab (Tiziana Life Sciences, New York, NY) has been granted Fast Track Designation by the Food and Drug Administration (FDA) for investigation as a potential treatment for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Foralumab is a fully human
- Once-Daily Pill Approved to Treat Forms of Astrocytoma and Oligodendrogliomahttps://practicalneurology.com/news/once-daily-pill-approved-to-treat-forms-of-astrocytoma-and-oligodendroglioma/2470553/The Food and Drug Administration (FDA) has approved Voranigo (vorasidenib; Servier, Boston, MA) for the treatment of adults and children aged ≥12 years with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutati
- Promising Results for Novel Sigma-1 Receptor Therapy as Alzheimer Treatmenthttps://practicalneurology.com/news/novel-sigma-1-receptor-therapy-slowed-clinical-progression-in-alzheimer-disease/2470543/Treatment with Anavex2-73 (blarcamesine; Anavex Life Sciences, New York, NY) for people with early Alzheimer disease (AD) was associated with slowed clinical progression in cognitive and functional outcomes. Anavex2-73 is a small-molecule activator of the sigma-1 receptor (SIGMAR1) that is orally
- Experimental Combo Treatment Reduced Alzheimer Disease-Associated Agitationhttps://practicalneurology.com/news/experimental-combo-treatment-reduced-alzheimer-disease-associated-agitation/2470535/Results of the ACCORD (NCT04797715) clinical trial presented at the 2024 meeting of the Alzheimer’s Association International Conference (AAIC) demonstrated that AXS-05 (dextromethorphan-bupropion; Axsome Therapeutics, New York, NY) treatment reduced agitation symptom relapse and was well-t
- Investigational Intradiscal Injection Improved Pain Associated with Lumbar Disc Herniationhttps://practicalneurology.com/news/investigational-intradiscal-injection-improved-pain-associated-with-lumbar-disc-herniation/2470528/People treated with experimental product SI-6603 (condoliase; Ferring Pharmaceuticals, Parsippany, NJ; Seikagaku, Tokyo, Japan) by a single intradiscal injection showed improvements in the radicular leg pain associated with their lumbar disc herniation (LDH). Early response data from a phase 3 st
- CMS Launches New Program to Support People with Dementia and their Caregivershttps://practicalneurology.com/news/cms-launches-new-program-to-support-people-with-dementia-and-their-caregivers/2470526/On July 1, 2024, the Centers for Medicare & Medicaid Services (CMS) announced the launch of the Guiding an Improved Dementia Experience (GUIDE) Model, a voluntary nationwide model test designed to support people with dementia and their caregivers. The GUIDE Model will be active for 8 years an
- Elevidys Receives Expanded Indication for Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/elevidys-receives-expanded-indication-for-dmd/2470516/The Food and Drug Administration (FDA) has broadened the approval for Elevidys (delandistrogene moxeparvovec-rokl; Sarepta Therapeutics, Cambridge, MA) as a treatment for patients diagnosed with Duchenne muscular dystrophy (DMD) aged ≥4 years with a confirmed mutation in the DMD gene, granting
- Wakix Treatment for Excessive Daytime Sleepiness in Pediatric Patients with Narcolepsy Approvedhttps://practicalneurology.com/news/wakix-treatment-for-excessive-daytime-sleepiness-in-pediatric-patients-with-narcolepsy-approved/2470515/The Food and Drug Administration (FDA) has approved Harmony Biosciences’ supplemental New Drug Application (sNDA) for Wakix (pitolisant; Harmony Biosciences, Plymouth Meeting, PA) for the treatment of excessive daytime sleepiness (EDS) in pediatric patients (aged 6 to <18 years) with nar
- Potentially Synergistic Effect Identified in Treatment with OnabotulinumtoxinA + Qulipta as a Prophylactic Polytherapy for Chronic Migrainehttps://practicalneurology.com/news/potentially-synergistic-effect-identified-in-treatment-with-onabotulinumtoxina-qulipta-as-a-prophylactic-polytherapy-for-chronic-migraine/2470509/A majority of people with chronic migraine treated with onabotulinumtoxinA experienced a potentially synergistic effect when Qulipta (atogepant; Abbvie, North Chicago, IL) was added to their prophylactic regimen. The results of a single-site real-world observational study were presented at the 66